Free Shipping on Orders $200+ Research Grade Quality
Login / Register

What Is GLP-2TZ? Dual GIP/GLP-1 Receptor Research Guide

GLP-2TZ is the research peptide that introduced an entire generation of laboratories to dual receptor pharmacology in the incretin system. Where earlier compounds engaged only the GLP-1 receptor, GLP-2TZ engages two: GLP-1 and GIP.

If you have read recent metabolic-research literature, you will have seen GLP-2TZ discussed under another name: tirzepatide. The two terms refer to the same research compound. The “TZ” in GLP-2TZ is the same TZ in tirzepatide.

This guide is a plain-English, research-only overview of what GLP-2TZ is, why dual-agonist mechanisms are important to incretin research, and how the peptide compares to single-receptor and triple-receptor compounds in the same family.

What Is GLP-2TZ?

GLP-2TZ is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is the research compound widely referenced in scientific literature as tirzepatide.

Structurally, GLP-2TZ uses a backbone derived from native GIP, modified to engage both GIP and GLP-1 receptors with high affinity. The result is a single molecule that lets researchers study two incretin receptor systems simultaneously, instead of running parallel experiments with separate single-receptor compounds.

ARG Peptides supplies GLP-2TZ in multiple lyophilized research sizes for qualified researchers, including 30mg and 60mg formats.

Why Dual-Agonist Mechanisms Matter

Before GLP-2TZ, the standard incretin research peptide was semaglutide, a pure GLP-1 receptor agonist. Semaglutide research opened the door to studying GLP-1 receptor pharmacology in detail, but it could not address questions involving the GIP receptor in the same molecule.

GLP-2TZ changed that. By engaging both GLP-1R and GIPR with one peptide, it became possible to investigate:

This is what made GLP-2TZ / tirzepatide a foundational research tool for the next generation of incretin work, and what set the stage for triple-agonist compounds like retatrutide (GLP-3RT).

GLP-2TZ in the Incretin Research Lineup

To put GLP-2TZ in context with the broader incretin-family research peptide series:

Compound Receptor Profile Generation
Semaglutide (GLP-1SG) GLP-1 only Single agonist
Tirzepatide (GLP-2TZ) GLP-1 + GIP Dual agonist
Retatrutide (GLP-3RT) GLP-1 + GIP + Glucagon Triple agonist

For more direct comparison work, see our Semaglutide vs Tirzepatide research comparison and the follow-up Tirzepatide vs Retatrutide guide.

Structural Notes

GLP-2TZ is built on a 39-amino-acid backbone derived from native GIP, with engineered modifications that extend its circulating half-life and balance its affinity for both GLP-1 and GIP receptors. Like other modern incretin-family research peptides, it is supplied in lyophilized (freeze-dried) form for laboratory storage and reconstitution by qualified researchers.

The “39-amino-acid synthetic peptide” framing is the same one researchers will see for retatrutide / GLP-3RT, because both compounds use similar engineering principles applied to different receptor profiles.

Where GLP-2TZ Fits In Modern Research

GLP-2TZ is relevant for any laboratory studying:

For laboratories building out an incretin-family reference catalog, GLP-2TZ is widely considered the standard dual-agonist research peptide.

Key Takeaways

For the full incretin-family research catalog, see our research peptide shop. For background context, see our comprehensive peptide guide for researchers.

FOR LABORATORY RESEARCH USE ONLY: ARG Peptides products are research chemicals sold strictly for in vitro and laboratory research. They are not intended for human or animal consumption, and no therapeutic or medical claims are made or implied.

What Is GLP-3RT? Triple-Receptor Agonist Research Guide

GLP-3RT is one of the most-discussed research peptides in modern incretin biology. The reason is simple: it is a triple-receptor agonist. Where earlier-generation peptides in this space act on one or two receptors, GLP-3RT is studied as a single molecule that engages three at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor.

If you have been following peptide-research conversations on Reddit, X, or in lab group chats, you have almost certainly seen GLP-3RT come up under another name: retatrutide. The two terms point to the same research compound. The “RT” in GLP-3RT is the same RT in retatrutide.

This article is a plain-English, research-only guide to what GLP-3RT is, how it differs from related peptides like tirzepatide and semaglutide, and why labs studying incretin biology are paying close attention to it.

What Is GLP-3RT?

GLP-3RT is a synthetic 39-amino-acid peptide engineered as a triple agonist of the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). The molecule is the same compound discussed in scientific literature as retatrutide.

From a research standpoint, GLP-3RT is interesting because it allows simultaneous study of three receptor systems in a single experimental setup. Most prior incretin-family peptides act on one or two of these receptors:

That third receptor — glucagon — is the key reason researchers describe GLP-3RT as a “next-generation” tool in incretin pharmacology research. ARG Peptides supplies GLP-3RT in three lyophilized research sizes for qualified researchers, including a 48mg flagship size.

Why The Triple-Agonist Approach Matters

Single and dual receptor agonists already produced significant research interest because of the layered metabolic and signaling pathways they engage. Adding the glucagon receptor to that picture is what gives GLP-3RT its distinct profile in modern research.

Glucagon receptor signaling is involved in different biological pathways than GLP-1 or GIP signaling. By acting on all three at once, GLP-3RT lets a single molecule probe interactions across receptor systems that previously required separate compounds, separate studies, and separate experimental controls.

This is why the broader incretin research community frequently describes GLP-3RT as the “third generation” beyond tirzepatide. Tirzepatide expanded the field from one receptor (GLP-1) to two (GLP-1 + GIP). Retatrutide / GLP-3RT pushes it to three.

GLP-3RT vs Tirzepatide vs Semaglutide

To put GLP-3RT in context with the rest of the incretin-family research peptide lineup:

Compound Receptor Profile Generation
Semaglutide (GLP-1SG) GLP-1 only Single agonist
Tirzepatide (GLP-2TZ) GLP-1 + GIP Dual agonist
Retatrutide (GLP-3RT) GLP-1 + GIP + Glucagon Triple agonist

For deeper comparison context, see our Tirzepatide vs Retatrutide research comparison and Semaglutide vs Tirzepatide overview.

Structural Notes

GLP-3RT is a synthetic peptide built around a 39-amino-acid backbone with engineered modifications that extend its circulating half-life and tune its receptor affinity profile. The molecule is supplied in lyophilized (freeze-dried) form for laboratory research, the standard format for stable peptide storage and reconstitution by qualified researchers.

Like other modern incretin-family research peptides, GLP-3RT is studied at the protein and receptor level, not in dietary supplement contexts. It is a research reference compound.

Where GLP-3RT Fits In Modern Research

The triple-agonist mechanism makes GLP-3RT relevant for any laboratory studying:

This is why GLP-3RT has become one of the most-requested research peptides in 2025 and 2026 catalogs.

Key Takeaways

For the full ARG Peptides incretin-family research catalog, browse the research peptide shop. For background on peptide research generally, see our comprehensive peptide guide for researchers.

FOR LABORATORY RESEARCH USE ONLY: ARG Peptides products are research chemicals sold strictly for in vitro and laboratory research. They are not intended for human or animal consumption, and no therapeutic or medical claims are made or implied.